Ligand Pharmaceuticals (LGND) Cash from Investing Activities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$94.3 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at -$94.3 million, down 2027.81% year-over-year; the trailing twelve-month figure through Mar 2026 was -$476.6 million (down 253.02% YoY), and the FY2025 annual result was -$377.3 million, down 162.64% from the prior year.
• Cash from Investing Activities came in at -$94.3 million for Q1 2026 at Ligand Pharmaceuticals, down from -$18.1 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $113.9 million in Q1 2022 to a low of -$353.4 million in Q3 2025.
• The 5-year median for Cash from Investing Activities is -$10.3 million (2023), against an average of -$27.3 million.
• Across the five-year window, Cash from Investing Activities jumped 229.64% in 2025 and tumbled 2027.81% in 2026, its largest moves.
• Ligand Pharmaceuticals' Cash from Investing Activities stood at -$7.3 million in 2022, then slumped by 41.19% to -$10.3 million in 2023, then slumped by 275.56% to -$38.6 million in 2024, then jumped by 53.13% to -$18.1 million in 2025, then sank by 421.14% to -$94.3 million in 2026.
• The last three Cash from Investing Activities figures came in at -$94.3 million (Q1 2026), -$18.1 million (Q4 2025), and -$353.4 million (Q3 2025), per Business Quant data.